Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15452456rdf:typepubmed:Citationlld:pubmed
pubmed-article:15452456lifeskim:mentionsumls-concept:C0007131lld:lifeskim
pubmed-article:15452456lifeskim:mentionsumls-concept:C0005516lld:lifeskim
pubmed-article:15452456lifeskim:mentionsumls-concept:C0281194lld:lifeskim
pubmed-article:15452456pubmed:issue5lld:pubmed
pubmed-article:15452456pubmed:dateCreated2004-9-28lld:pubmed
pubmed-article:15452456pubmed:abstractTextIdentification of biomarkers is one of the most promising approaches for the detection of early malignant or even premalignant lesions with the chance of diagnosing early stages of non-small cell lung cancer that could be treated curatively. Alterations of chromosomes (3p, 5q, 9p), genes (Rb, C-myc, C-mos, hTERT), proteins (p16, p53, K-ras, hnRNP A2/B1, MCM2, EGFR, erbB-2, erbB-3, erbB-4) and others can be found in lung cancer. Some of these occur at early stages of the disease and few could serve as potential screening markers. The actual literature is reviewed and the relevance of the different biomarkers for early lung cancer detection is discussed.lld:pubmed
pubmed-article:15452456pubmed:languageenglld:pubmed
pubmed-article:15452456pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15452456pubmed:citationSubsetIMlld:pubmed
pubmed-article:15452456pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15452456pubmed:statusMEDLINElld:pubmed
pubmed-article:15452456pubmed:monthOctlld:pubmed
pubmed-article:15452456pubmed:issn0959-8278lld:pubmed
pubmed-article:15452456pubmed:authorpubmed-author:HilbeWWlld:pubmed
pubmed-article:15452456pubmed:authorpubmed-author:GreigWWlld:pubmed
pubmed-article:15452456pubmed:authorpubmed-author:ZhaoX NXNlld:pubmed
pubmed-article:15452456pubmed:authorpubmed-author:DirnhoferSSlld:pubmed
pubmed-article:15452456pubmed:issnTypePrintlld:pubmed
pubmed-article:15452456pubmed:volume13lld:pubmed
pubmed-article:15452456pubmed:ownerNLMlld:pubmed
pubmed-article:15452456pubmed:authorsCompleteYlld:pubmed
pubmed-article:15452456pubmed:pagination425-36lld:pubmed
pubmed-article:15452456pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:15452456pubmed:meshHeadingpubmed-meshheading:15452456...lld:pubmed
pubmed-article:15452456pubmed:meshHeadingpubmed-meshheading:15452456...lld:pubmed
pubmed-article:15452456pubmed:meshHeadingpubmed-meshheading:15452456...lld:pubmed
pubmed-article:15452456pubmed:meshHeadingpubmed-meshheading:15452456...lld:pubmed
pubmed-article:15452456pubmed:meshHeadingpubmed-meshheading:15452456...lld:pubmed
pubmed-article:15452456pubmed:meshHeadingpubmed-meshheading:15452456...lld:pubmed
pubmed-article:15452456pubmed:meshHeadingpubmed-meshheading:15452456...lld:pubmed
pubmed-article:15452456pubmed:year2004lld:pubmed
pubmed-article:15452456pubmed:articleTitleBiomarkers in non-small cell lung cancer prevention.lld:pubmed
pubmed-article:15452456pubmed:affiliationDepartment of General Internal Medicine, Oncology, University Hospital, Anichstrasse 35, A-6020 Innsbruck, Austria. wolfgang.hilbe@uibk.ac.atlld:pubmed
pubmed-article:15452456pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15452456pubmed:publicationTypeReviewlld:pubmed
pubmed-article:15452456pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed